Asian Business Management Group

Asian Business Management Group (ABMG) was a specialized contract research organization (CRO) and regulatory consulting firm focused on the Asia-Pacific region. The company provided comprehensive services including clinical trial management, regulatory affairs, and market entry strategies for pharmaceutical and medical device companies. ABMG was particularly known for its expertise in navigating the complex regulatory landscapes of China, Taiwan, and other Asian markets. In 2018, the company was acquired by dMed Biopharmaceutical, which subsequently merged with Clinipace to form the global CRO known as Caidya. The integration of ABMG's regional expertise significantly strengthened the acquirer's ability to support global drug development programs in Asia.